BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol. 2001;96:635-643. [PMID: 11280528 DOI: 10.1111/j.1572-0241.2001.03671.x] [Cited by in Crossref: 234] [Cited by in F6Publishing: 159] [Article Influence: 11.1] [Reference Citation Analysis]
Number Citing Articles
1 Gonvers J, Juillerat P, Mottet C, Felley C, Burnand B, Vader J, Michetti P, Froehlich F. Maintenance of Remission in Crohn’s Disease. Digestion 2005;71:41-8. [DOI: 10.1159/000083872] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
2 Palomba S, Manguso F, Orio F, Russo T, Oppedisano R, Sacchinelli A, Falbo A, Tolino A, Zullo F, Mastrantonio P. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study. Menopause 2008;15:730-6. [DOI: 10.1097/gme.0b013e318159f190] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
3 Bonner GF. Using COX-2 inhibitors in IBD: anti-inflammatories inflame a controversy. Am J Gastroenterol. 2002;97:783-785. [PMID: 12003408 DOI: 10.1111/j.1572-0241.2002.05592.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
4 Horimoto AM, Silveira AF, Costa IP. Familial autoimmunity and polyautoimmunity in 60 Brazilian Midwest patients with systemic sclerosis. Rev Bras Reumatol 2016:S0482-5004(15)00164-3. [PMID: 26809482 DOI: 10.1016/j.rbr.2015.09.002] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
5 Siddiqui MAA, Scott LJ. Infliximab: A Review of its Use in Crohn???s Disease and Rheumatoid Arthritis. Drugs 2005;65:2179-208. [DOI: 10.2165/00003495-200565150-00014] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 3.6] [Reference Citation Analysis]
6 Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008;135:1442-1447. [PMID: 18848556 DOI: 10.1053/j.gastro.2008.09.053] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 5.4] [Reference Citation Analysis]
7 Masunaga Y, Ohno K, Ogawa R, Hashiguchi M, Echizen H, Ogata H. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007;41:21-28. [PMID: 17200426 DOI: 10.1345/aph.1h219] [Cited by in Crossref: 59] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
8 Colombel JF, Rutgeerts PJ, Sandborn WJ, Yang M, Camez A, Pollack PF, Thakkar RB, Robinson AM, Chen N, Mulani PM, Chao J. Adalimumab induces deep remission in patients with Crohn's disease. Clin Gastroenterol Hepatol 2014; 12: 414-22. e5. [PMID: 23856361 DOI: 10.1016/j.cgh.2013.06.019] [Cited by in Crossref: 149] [Cited by in F6Publishing: 133] [Article Influence: 16.6] [Reference Citation Analysis]
9 Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol. 2002;97:2962-2972. [PMID: 12492177 DOI: 10.1111/j.1572-0241.2002.07093.x] [Cited by in Crossref: 138] [Cited by in F6Publishing: 130] [Article Influence: 7.3] [Reference Citation Analysis]
10 Holdam AS, Bager P, Dahlerup JF. Biological therapy increases the health-related quality of life in patients with inflammatory bowel disease in a clinical setting. Scand J Gastroenterol 2016;51:706-11. [PMID: 26794211 DOI: 10.3109/00365521.2015.1136352] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
11 Malone DC, Waters HC, Van Den Bos J, Popp J, Draaghtel K, Rahman MI. A claims-based Markov model for Crohn’s disease: Disease severity and costs in Crohn’s disease. Alimentary Pharmacology & Therapeutics 2010;32:448-58. [DOI: 10.1111/j.1365-2036.2010.04356.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
12 Thia KT, Li M, Ling KL, Kong SC, Ooi CJ. Azathioprine is effective in corticosteroid-dependent Asian inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17:809-815. [PMID: 20645318 DOI: 10.1002/ibd.21382] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
13 Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology. 2007;133:1106-1112. [PMID: 17764676 DOI: 10.1053/j.gastro.2007.07.019] [Cited by in Crossref: 237] [Cited by in F6Publishing: 194] [Article Influence: 15.8] [Reference Citation Analysis]
14 Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, Binion DG. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005;21:733-738. [PMID: 15771759 DOI: 10.1111/j.1365-2036.2005.02405.x] [Cited by in Crossref: 196] [Cited by in F6Publishing: 168] [Article Influence: 11.5] [Reference Citation Analysis]
15 Ouyang Q, Tandon R, Goh KL, Pan GZ, Fock KM, Fiocchi C, Lam SK, Xiao SD. Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol 2006;21:1772-82. [PMID: 17074013 DOI: 10.1111/j.1440-1746.2006.04674.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 4.5] [Reference Citation Analysis]
16 Tsertsvadze A, Gurung T, Court R, Clarke A, Sutcliffe P. Clinical effectiveness and cost-effectiveness of elemental nutrition for the maintenance of remission in Crohn's disease: a systematic review and meta-analysis. Health Technol Assess 2015;19:1-138. [PMID: 25831484 DOI: 10.3310/hta19260] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
17 Cheerva A, Dillard R, Bertolone S. Extracorporeal photopheresis for the treatment of severe, refractory steroid dependent pediatric Crohn's Disease. J Clin Apher 2013;28:381-6. [PMID: 23720057 DOI: 10.1002/jca.21275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
18 Katz JA. Treatment of inflammatory bowel disease with corticosteroids. Gastroenterol Clin North Am. 2004;33:171-189, vii. [PMID: 15177533 DOI: 10.1016/j.gtc.2004.02.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
19 Reddy SI, Friedman S, Telford JJ, Strate L, Ookubo R, Banks PA. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol. 2005;100:1357-1361. [PMID: 15929770 DOI: 10.1111/j.1572-0241.2005.40849.x] [Cited by in Crossref: 108] [Cited by in F6Publishing: 95] [Article Influence: 6.4] [Reference Citation Analysis]
20 Booya F, Akram S, Fletcher JG, Huprich JE, Johnson CD, Fidler JL, Barlow JM, Solem CA, Sandborn WJ, Loftus EV. CT enterography and fistulizing Crohn’s disease: clinical benefit and radiographic findings. Abdom Imaging. 2009;34:467-475. [PMID: 18551336 DOI: 10.1007/s00261-008-9419-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 4.8] [Reference Citation Analysis]
21 Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 2007;26:987-1003. [PMID: 17877506 DOI: 10.1111/j.1365-2036.2007.03455.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
22 Gordon M, Naidoo K, Thomas AG, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2011;:CD008414. [PMID: 21249709 DOI: 10.1002/14651858.CD008414.pub2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
23 Freeman K, Connock M, Auguste P, Taylor-Phillips S, Mistry H, Shyangdan D, Court R, Arasaradnam R, Sutcliffe P, Clarke A. Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF-α) inhibitors [LISA-TRACKER® enzyme-linked immunosorbent assay (ELISA) kits, TNF-α-Blocker ELISA kits and Promonitor® ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling. Health Technol Assess 2016;20:1-288. [PMID: 27845027 DOI: 10.3310/hta20830] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
24 Papi C, Aratari A, Tornatore V, Koch M, Capurso L, Caprilli R. Long-term prevention of post-operative recurrence in Crohn’s disease cannot be affected by mesalazine. J Crohns Colitis. 2009;3:109-114. [PMID: 21172253 DOI: 10.1016/j.crohns.2008.12.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
25 Büning C, Lochs H. Conventional therapy for Crohn’s disease. World J Gastroenterol 2006; 12(30): 4794-4806 [PMID: 16937460 DOI: 10.3748/wjg.v12.i30.4794] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
26 Abir F, Alva S, Kaminski DL, Longo WE. The role of arachidonic acid regulatory enzymes in colorectal disease. Dis Colon Rectum. 2005;48:1471-1483. [PMID: 15868226 DOI: 10.1007/s10350-005-0015-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
27 Feuerstein JD, Cheifetz AS. Crohn Disease: Epidemiology, Diagnosis, and Management. Mayo Clin Proc. 2017;92:1088-1103. [PMID: 28601423 DOI: 10.1016/j.mayocp.2017.04.010] [Cited by in Crossref: 111] [Cited by in F6Publishing: 92] [Article Influence: 22.2] [Reference Citation Analysis]
28 Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2010;(12):CD008870. [PMID: 21154400 DOI: 10.1002/14651858.cd008870] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
29 Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, Ghosh S, Sandborn WJ. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology 2018;154:1660-71. [PMID: 29409871 DOI: 10.1053/j.gastro.2018.01.043] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 21.5] [Reference Citation Analysis]
30 Palomba S, Orio F, Manguso F, Falbo A, Russo T, Tolino A, Tauchmanovà L, Colao A, Doldo P, Mastrantonio P, Zullo F. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. Osteoporos Int 2005;16:1141-9. [DOI: 10.1007/s00198-005-1927-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
31 Ruthruff B. Clinical review of Crohn?s disease. J Amer Acad Nurse Practitioners 2007;19:392-7. [DOI: 10.1111/j.1745-7599.2007.00242.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
32 Leung WK, Ng SC, Chow DK, Lao WC, Leung VK, Li MK, Hui YT, Ng SS, Hui AJ, Lai ST. Use of biologics for inflammatory bowel disease in Hong Kong: consensus statement. Hong Kong Med J. 2013;19:61-68. [PMID: 23378357 DOI: 10.1007/s00535-012-0673-1] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 8.2] [Reference Citation Analysis]
33 Michetti P, Mottet C, Juillerat P, Pittet V, Felley C, Vader J, Gonvers J, Froehlich F. Severe and Steroid-Resistant Crohn’s Disease. Digestion 2008;76:99-108. [DOI: 10.1159/000111023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
34 Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135:1130-1141. [PMID: 18706417 DOI: 10.1053/j.gastro.2008.07.014] [Cited by in Crossref: 530] [Cited by in F6Publishing: 480] [Article Influence: 37.9] [Reference Citation Analysis]
35 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
36 Jiang L, Xia B, Li J, Ye M, Yan W, Deng C, Ding Y, Luo H, Hou W, Zhao Q, Liu N, Ren H, Hou X, Xu H. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis 2006;12:212-7. [PMID: 16534423 DOI: 10.1097/01.MIB.0000201098.26450.ae] [Cited by in Crossref: 107] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
37 Marier J, Mouksassi M, Gosselin NH, Beliveau M, Cyran J, Wallens J. Population Pharmacokinetics of Teduglutide Following Repeated Subcutanenous Administrations in Healthy Participants and in Patients With Short Bowel Syndrome and Crohn's Disease. The Journal of Clinical Pharmacology 2010;50:36-49. [DOI: 10.1177/0091270009342252] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
38 Lichtenstein GR. PRO: Maintenance Therapy Is Superior to Episodic Therapy. Am J Gastroenterology 2005;100:1433-5. [DOI: 10.1111/j.1572-0241.2005.50622_1.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
39 Friedman S. General principles of medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am. 2004;33:191-208, viii. [PMID: 15177534 DOI: 10.1016/j.gtc.2004.02.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
40 van der Woude JC, Stokkers P, van Bodegraven AA, Van Assche G, Hebzda Z, Paradowski L, Dʼhaens G, Ghosh S, Feagan B, Rutgeerts P, Dijkstra G, de Jong DJ, Oldenburg B, Farhan M, Richard T, Dean Y, Hommes DW. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohnʼs disease†: . Inflammatory Bowel Diseases 2010;16:1708-16. [DOI: 10.1002/ibd.21252] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
41 Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn’s disease. Am J Gastroenterol. 2006;101:1030-1038. [PMID: 16606351 DOI: 10.1111/j.1572-0241.2006.00463.x] [Cited by in Crossref: 139] [Cited by in F6Publishing: 124] [Article Influence: 8.7] [Reference Citation Analysis]
42 Swaminath A, Kornbluth A. Optimizing drug therapy in inflammatory bowel disease. Curr Gastroenterol Rep 2007;9:513-20. [DOI: 10.1007/s11894-007-0068-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
43 Nielsen AA, Nielsen JN, Grønbæk H, Eivindson M, Vind I, Munkholm P, Brandslund I, Hey H. Impact of Enteral Supplements Enriched with ω–3 Fatty Acids and/or ω–6 Fatty Acids, Arginine and Ribonucleic Acid Compounds on Leptin Levels and Nutritional Status in Active Crohn’s Disease Treated with Prednisolone. Digestion 2007;75:10-6. [DOI: 10.1159/000101560] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
44 Juillerat P, Pittet V, Mottet C, Felley C, Gonvers J, Vader J, Burnand B, Froehlich F, Wolters FL, Stockbrügger RW, Michetti P; the EC-IBD Group. Appropriateness of early management of newly diagnosed Crohn's disease in a European population-based cohort. Scandinavian Journal of Gastroenterology 2010;45:1449-56. [DOI: 10.3109/00365521.2010.505660] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
45 Smith GD, Watson R, Thompson DR. Older people and inflammatory bowel disease: a systematic review. Journal of Clinical Nursing 2008;17:400-6. [DOI: 10.1111/j.1365-2702.2008.02577.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
46 Proksell SS, Greer JB, Theisen BK, Davis PL, Rosh JR, Keljo DJ, Goyal A, Shah SA, Brand MH, Herfarth HH, Cross RK, Siegel CA, Koltun WA, Isaacs KL, Regueiro MD. IBD LIVE Case Series: Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn's Colitis? Inflamm Bowel Dis 2018;24:698-713. [PMID: 29562279 DOI: 10.1093/ibd/izx114] [Reference Citation Analysis]
47 Hofer KN. Oral Budesonide in the Management of Crohn's Disease. Ann Pharmacother 2003;37:1457-64. [DOI: 10.1345/aph.1d059] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Waters HC, Hilliard RP, Teng E, Rahman MI, Ferrer R, Pulicharam J, Nejadnik B. An Exploratory Analysis of Healthcare Costs and Utilization of Pediatric Patients with Crohn’s Disease. Dig Dis Sci 2009;54:2650-4. [DOI: 10.1007/s10620-008-0670-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Caviglia R, Boškoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion on Drug Safety 2008;7:617-32. [DOI: 10.1517/14740338.7.5.617] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
50 Dziki A, Galbfach P. Crohn's disease--when to operate? Acta Chir Iugosl 2004;51:61-8. [PMID: 15771291 DOI: 10.2298/aci0402061d] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
51 Afif W, Sandborn WJ, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, Loftus EV. Risk Factors for Lymphoma in Patients with Inflammatory Bowel Disease: A Case-control Study. Inflammatory Bowel Diseases 2013;19:1384-9. [DOI: 10.1097/mib.0b013e318281325e] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
52 Michetti P, Juillerat P, Mottet C, Gonvers J, Burnand B, Vader J, Froehlich F, Felley C. Therapy of Mild to Moderate Luminal Crohn’s Disease. Digestion 2005;71:13-8. [DOI: 10.1159/000083866] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
53 Simondi D, Mengozzi G, Betteto S, Bonardi R, Ghignone RP, Fagoonee S, Pellicano R, Sguazzini C, Pagni R, Rizzetto M. Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:645-651. [PMID: 18240283 DOI: 10.1002/ibd.20368] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
54 Steinhart AH, Forbes A, Mills EC, Rodgers-Gray BS, Travis SP. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2007;25:1389-99. [PMID: 17539978 DOI: 10.1111/j.1365-2036.2007.03324.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
55 Sands BE, Arsenault JE, Rosen MJ, Alsahli M, Bailen L, Banks P, Bensen S, Bousvaros A, Cave D, Cooley JS, Cooper HL, Edwards ST, Farrell RJ, Griffin MJ, Hay DW, John A, Lidofsky S, Olans LB, Peppercorn MA, Rothstein RI, Roy MA, Saletta MJ, Shah SA, Warner AS, Wolf JL, Vecchio J, Winter HS, Zawacki JK. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol. 2003;98:2712-2718. [PMID: 14687822 DOI: 10.1111/j.1572-0241.2003.08674.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 5.4] [Reference Citation Analysis]
56 Hanauer SB. The case for using 5-aminosalicyclates in Crohn's disease: pro. Inflamm Bowel Dis 2005;11:609-12. [PMID: 15905710 DOI: 10.1097/01.mib.0000160743.24772.69] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
57 Babu D, Lee JS, Park SY, Thapa D, Choi MK, Kim AR, Park YJ, Kim JA. Involvement of NF-kappaB in the inhibitory actions of Platycarya strobilacea on the TNF-alpha-induced monocyte adhesion to colon epithelial cells and chemokine expression. Arch Pharm Res 2008;31:727-35. [PMID: 18563354 DOI: 10.1007/s12272-001-1219-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
58 Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:674-688. [PMID: 18532990 DOI: 10.1111/j.1365-2036.2008.03753.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 4.9] [Reference Citation Analysis]
59 Sandborn WJ, Löfberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR. Budesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol. 2005;100:1780-1787. [PMID: 16086715 DOI: 10.1111/j.1572-0241.2005.41992.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 5.5] [Reference Citation Analysis]
60 Arumugam S, Thandavarayan RA, Pitchaimani V, Karuppagounder V, Harima M, Nishizawa Y, Sasaki K, Suzuki K, Konishi T, Watanabe K. Prevention of DSS induced acute colitis by Petit Vert, a newly developed function improved vegetable, in mice. PharmaNutrition 2014;2:129-34. [DOI: 10.1016/j.phanu.2013.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
61 Ouyang Q, Hu PJ, Qian JM, Zheng JJ, Hu RW. Consensus on the management of inflammatory bowel disease in China in 2007. J Dig Dis. 2008;9:52-62. [PMID: 18251795 DOI: 10.1111/j.1443-9573.2007.00320.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
62 APDW2004 Chinese IBD Working Group. Retrospective analysis of 515 cases of Crohn's disease hospitalization in China: nationwide study from 1990 to 2003. J Gastroenterol Hepatol. 2006;21:1009-1015. [PMID: 16724987 DOI: 10.1111/j.1440-1746.2006.04140.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 2.7] [Reference Citation Analysis]
63 Clark M, Colombel J, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006. Gastroenterology 2007;133:312-39. [DOI: 10.1053/j.gastro.2007.05.006] [Cited by in Crossref: 157] [Cited by in F6Publishing: 145] [Article Influence: 10.5] [Reference Citation Analysis]
64 Abbas Z, Khan R, Abid S, Hamid S, Shah H, Jafri W. Is Crohn's Disease in Pakistan Less Severe than in the West? Trop Doct 2004;34:39-41. [DOI: 10.1177/004947550403400120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
65 Tung JK, Warner AS. Colonic inflammatory bowel disease. Medical therapies for colonic Crohn's disease and ulcerative colitis. Postgrad Med 2002;112:45-8, 51. [PMID: 12462184 DOI: 10.3810/pgm.2002.11.1344] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, Londhe A, Sandborn WJ. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014;109:212-223. [PMID: 24394749 DOI: 10.1038/ajg.2013.441] [Cited by in Crossref: 125] [Cited by in F6Publishing: 107] [Article Influence: 15.6] [Reference Citation Analysis]
67 Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707-712. [PMID: 16043984 DOI: 10.1097/01.mib.0000173271.18319.53] [Cited by in Crossref: 363] [Cited by in F6Publishing: 143] [Article Influence: 21.4] [Reference Citation Analysis]
68 Esrailian E, Spiegel BM, Targownik LE, Dubinsky MC, Targan SR, Gralnek IM. Differences in the management of Crohn’s disease among experts and community providers, based on a national survey of sample case vignettes. Aliment Pharmacol Ther. 2007;26:1005-1018. [PMID: 17877507 DOI: 10.1111/j.1365-2036.2007.03445.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
69 Lim CS, Moon W, Park SJ, Park MI, Kim HH, Kim JB, Choi JM, Chang HK, Lee SH. A rare case of free bowel perforation associated with infliximab treatment for stricturing Crohn’s disease. Korean J Gastroenterol. 2013;62:169-173. [PMID: 24077628 DOI: 10.4166/kjg.2013.62.3.169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
70 Colombel J. Efficacy and safety of adalimumab for the treatment of Crohn’s disease in adults. Expert Review of Gastroenterology & Hepatology 2014;2:163-76. [DOI: 10.1586/17474124.2.2.163] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
71 Ghosh N, Chaki R, Mandal V, Lin GD, Mandal SC. Mechanisms and Efficacy of Immunobiologic Therapies for Inflammatory Bowel Diseases. International Reviews of Immunology 2010;29:4-37. [DOI: 10.3109/08830180903437212] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
72 Michetti P, Juillerat P, Mottet C, Pittet V, Gonvers J, Vader J, Froehlich F, Felley C. Mild-to-Moderate Active Luminal Crohn’s Disease. Digestion 2008;76:92-8. [DOI: 10.1159/000111022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
73 Fatahzadeh M. Inflammatory bowel disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:e1-10. [PMID: 19836703 DOI: 10.1016/j.tripleo.2009.07.035] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
74 Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657. [PMID: 17499606 DOI: 10.1016/s0140-6736(07)60751-x] [Cited by in Crossref: 1121] [Cited by in F6Publishing: 487] [Article Influence: 74.7] [Reference Citation Analysis]
75 Vavricka SR, Schoepfer AM, Scharl M, Rogler G. Steroid Use in Crohn’s Disease. Drugs 2014;74:313-24. [DOI: 10.1007/s40265-014-0183-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
76 Harrell LE, Hanauer SB. Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterology Clinics of North America 2004;33:303-17. [DOI: 10.1016/j.gtc.2004.02.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
77 Mondal P, Trigun SK. Pannexin1 as a novel cerebral target in pathogenesis of hepatic encephalopathy. Metab Brain Dis 2014;29:1007-15. [DOI: 10.1007/s11011-014-9556-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
78 Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment Pharmacol Ther. 2003;18:1113-1120. [PMID: 14653831 DOI: 10.1046/j.1365-2036.2003.01793.x] [Cited by in Crossref: 146] [Cited by in F6Publishing: 111] [Article Influence: 8.1] [Reference Citation Analysis]
79 DiNicola CA, Zand A, Hommes DW. Autologous hematopoietic stem cells for refractory Crohn's disease. Expert Opin Biol Ther 2017;17:555-64. [PMID: 28326848 DOI: 10.1080/14712598.2017.1305355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
80 Litcher-Kelly L, Kellerman Q, Hanauer SB, Stone AA. Feasibility and utility of an electronic diary to assess self-report symptoms in patients with inflammatory bowel disease. Ann Behav Med 2007;33:207-12. [PMID: 17447873 DOI: 10.1007/BF02879902] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
81 Colombel JF, Peyrin-Biroulet L. Natalizumab: a promising treatment for Crohn's disease. Expert Rev Clin Immunol 2006;2:677-89. [PMID: 20477624 DOI: 10.1586/1744666X.2.5.677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
82 Harrison J, Hanauer SB. Medical treatment of Crohn's disease. Gastroenterology Clinics of North America 2002;31:167-84. [DOI: 10.1016/s0889-8553(01)00011-5] [Cited by in Crossref: 9] [Article Influence: 0.5] [Reference Citation Analysis]
83 Trindade AJ, Ehrlich A, Kornbluth A, Ullman TA. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis. 2011;17:599-604. [PMID: 20848512 DOI: 10.1002/ibd.21310] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 5.8] [Reference Citation Analysis]
84 Ooi CJ, Makharia GK, Hilmi I, Gibson PR, Fock KM, Ahuja V, Ling KL, Lim WC, Thia KT, Wei SC, Leung WK, Koh PK, Gearry RB, Goh KL, Ouyang Q, Sollano J, Manatsathit S, de Silva HJ, Rerknimitr R, Pisespongsa P, Abu Hassan MR, Sung J, Hibi T, Boey CC, Moran N, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease. Asia-Pacific consensus statements on Crohn's disease. Part 2: Management. J Gastroenterol Hepatol. 2016;31:56-68. [PMID: 25819311 DOI: 10.1111/jgh.12958] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
85 Zhu W, Li Y, Gong J, Zuo L, Zhang W, Cao L, Gu L, Guo Z, Li N, Li J. Tripterygium wilfordii Hook. f. versus azathioprine for prevention of postoperative recurrence in patients with Crohn's disease: a randomized clinical trial. Dig Liver Dis 2015;47:14-9. [PMID: 25445405 DOI: 10.1016/j.dld.2014.09.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
86 Ardizzone S, Bianchi Porro G. Biologic Therapy for Inflammatory Bowel Disease: . Drugs 2005;65:2253-86. [DOI: 10.2165/00003495-200565160-00002] [Cited by in Crossref: 178] [Cited by in F6Publishing: 178] [Article Influence: 10.5] [Reference Citation Analysis]
87 Pierce CA, Baker JJ. A Nursing Process Model: Quantifying Infusion Therapy Resource Consumption. Journal of Infusion Nursing 2004;27:232-44. [DOI: 10.1097/00129804-200407000-00008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
88 Morini S, Hassan C, Lorenzetti R, Zullo A, Cerro P, Winn S, Giustini M, Taggi F. Long-term outcome of endoscopic pneumatic dilatation in Crohn’s disease. Digestive and Liver Disease 2003;35:893-7. [DOI: 10.1016/j.dld.2003.06.001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
89 Goldfarb NI, Pizzi LT, Fuhr JP, Salvador C, Sikirica V, Kornbluth A, Lewis B. Diagnosing Crohn's disease: an economic analysis comparing wireless capsule endoscopy with traditional diagnostic procedures. Dis Manag. 2004;7:292-304. [PMID: 15671786 DOI: 10.1089/dis.2004.7.292] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
90 Reddy BV, Kuruba KK, Yalamanchili S, Mupparapu M. Granulomatous Diseases Affecting Jaws. Dent Clin North Am 2016;60:195-234. [PMID: 26614955 DOI: 10.1016/j.cden.2015.08.007] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
91 Schwanke RC, Marcon R, Bento AF, Calixto JB. EPA- and DHA-derived resolvins' actions in inflammatory bowel disease. Eur J Pharmacol 2016;785:156-64. [PMID: 26325092 DOI: 10.1016/j.ejphar.2015.08.050] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
92 Aboura I, Nani A, Belarbi M, Murtaza B, Fluckiger A, Dumont A, Benammar C, Tounsi MS, Ghiringhelli F, Rialland M, Khan NA, Hichami A. Protective effects of polyphenol-rich infusions from carob (Ceratonia siliqua) leaves and cladodes of Opuntia ficus-indica against inflammation associated with diet-induced obesity and DSS-induced colitis in Swiss mice. Biomed Pharmacother 2017;96:1022-35. [PMID: 29221725 DOI: 10.1016/j.biopha.2017.11.125] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
93 Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008;64:753-67. [DOI: 10.1007/s00228-008-0478-6] [Cited by in Crossref: 240] [Cited by in F6Publishing: 191] [Article Influence: 17.1] [Reference Citation Analysis]
94 Dayharsh GA, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, Macon WR, Burgart LJ. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002;122:72-77. [PMID: 11781282 DOI: 10.1053/gast.2002.30328] [Cited by in Crossref: 188] [Cited by in F6Publishing: 164] [Article Influence: 9.4] [Reference Citation Analysis]
95 Strong SA, Koltun WA, Hyman NH, Buie DW. Practice Parameters for the Surgical Management of Crohn's Disease. Diseases of the Colon & Rectum 2007;50:1735-46. [DOI: 10.1007/s10350-007-9012-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
96 Kane SV, Loftus EV Jr, Dubinsky MC, Sederman R. Disease perceptions among people with Crohn's disease. Inflamm Bowel Dis 2008;14:1097-101. [PMID: 18338774 DOI: 10.1002/ibd.20418] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
97 Boirivant M, Cossu A. Inflammatory bowel disease. Oral Dis. 2012;18:1-15. [PMID: 21564424 DOI: 10.1111/j.1601-0825.2011.01811.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
98 Tawfik DI, Osman AS, Tolba HM, Khattab A, Abdel-Salam LO, Kamel MM. Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn's disease in rats. Neuropeptides 2016;59:39-45. [PMID: 27392602 DOI: 10.1016/j.npep.2016.06.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
99 Hanauer SB. Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20 Suppl 4:60-65. [PMID: 15352896 DOI: 10.1111/j.1365-2036.2004.02048.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
100 Holmes E, Wijeyesekera A, Taylor-Robinson SD, Nicholson JK. The promise of metabolic phenotyping in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 2015;12:458-71. [PMID: 26194948 DOI: 10.1038/nrgastro.2015.114] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
101 Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease. Am J Gastroenterol 2009;104:2524-33. [DOI: 10.1038/ajg.2009.322] [Cited by in Crossref: 136] [Cited by in F6Publishing: 120] [Article Influence: 10.5] [Reference Citation Analysis]
102 Marier JF, Beliveau M, Mouksassi MS, Shaw P, Cyran J, Kesavan J, Wallens J, Zahir H, Wells D, Caminis J. Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects. J Clin Pharmacol. 2008;48:1289-1299. [PMID: 18974283 DOI: 10.1177/0091270008320605] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
103 Sansó Sureda A, Rocamora Durán V, Sapiña Camaró A, Royo Escosa V, Bosque López MJ. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis]. Gastroenterol Hepatol 2011;34:546-50. [PMID: 21665330 DOI: 10.1016/j.gastrohep.2011.04.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
104 Park JJ, Yang SK, Ye BD, Kim JW, Park DI, Yoon H, Im JP, Lee KM, Yoon SN, Lee H; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. [Second Korean Guidelines for the Management of Crohn's Disease]. Korean J Gastroenterol 2017;69:29-54. [PMID: 28135790 DOI: 10.4166/kjg.2017.69.1.29] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
105 Horimoto AM, Silveira AF, da Costa IP. Familial autoimmunity and polyautoimmunity in 60 Brazilian Midwest patients with systemic sclerosis. Rev Bras Reumatol Engl Ed 2016;56:314-22. [PMID: 27476624 DOI: 10.1016/j.rbre.2016.01.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan JG, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol 2018;113:1678-88. [PMID: 30022113 DOI: 10.1038/s41395-018-0202-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
107 Reinisch W, Miehsler W, Dejaco C, Harrer M, Waldhoer T, Lichtenberger C, Vogelsang H. An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia: ROFECOXIB IN IBD-ASSOCIATED PERIPHERAL ARTHRITIS AND ARTHRALGIA. Alimentary Pharmacology & Therapeutics 2003;17:1371-80. [DOI: 10.1046/j.1365-2036.2003.01596.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
108 Stokkers PC, Hommes DW. New cytokine therapeutics for inflammatory bowel disease. Cytokine. 2004;28:167-173. [PMID: 15588691 DOI: 10.1016/j.cyto.2004.07.012] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 3.0] [Reference Citation Analysis]
109 Regnault H, Bourrier A, Lalande V, Nion-larmurier I, Sokol H, Seksik P, Barbut F, Cosnes J, Beaugerie L. Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: A retrospective assessment. Digestive and Liver Disease 2014;46:1086-92. [DOI: 10.1016/j.dld.2014.09.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
110 Wilhelm SM, Taylor JD, Osiecki LL, Kale-pradhan PB. Novel Therapies for Crohn's Disease: Focus on Immunomodulators and Antibiotics. Ann Pharmacother 2006;40:1804-13. [DOI: 10.1345/aph.1h038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
111 Doğan M, Özcan S, Acartürk G, Özdemir Ç. Conjunctival Impression Cytology and Tear-Film Changes in Patients With Inflammatory Bowel Disease. Eye & Contact Lens: Science & Clinical Practice 2018;44:S420-5. [DOI: 10.1097/icl.0000000000000537] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
112 Pardi DS, Loftus EV, Camilleri M. Treatment of Inflammatory Bowel Disease in the Elderly: An Update. Drugs & Aging 2002;19:355-63. [DOI: 10.2165/00002512-200219050-00004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.3] [Reference Citation Analysis]
113 Michetti P, Mottet C, Juillerat P, Felley C, Vader JP, Burnand B, Gonvers JJ, Froehlich F. Severe and steroid-resistant Crohn's disease. Digestion 2005;71:19-25. [PMID: 15711044 DOI: 10.1159/000083867] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
114 Nielsen AA, Jorgensen LGM, Nielsen JN, Eivindson M, Gronbaek H, Vind I, Hougaard DM, Skogstrand K, Jensen S, Munkholm P, Brandslund I, Hey H. Omega-3 fatty acids inhibit an increase of proinflammatory cytokines in patients with active Crohn's disease compared with omega-6 fatty acids. Aliment Pharmacol Ther 2005;22:1121-8. [DOI: 10.1111/j.1365-2036.2005.02698.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
115 Ligumsky M, Badaan S, Lewis H, Meirow D. Effects of 6-mercaptopurine treatment on sperm production and reproductive performance: A study in male mice. Scandinavian Journal of Gastroenterology 2009;40:444-9. [DOI: 10.1080/00365520510011597] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
116 Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104:465-83; quiz 464, 484. [PMID: 19174807 DOI: 10.1038/ajg.2008.168] [Cited by in Crossref: 606] [Cited by in F6Publishing: 516] [Article Influence: 46.6] [Reference Citation Analysis]
117 Lee N, Radford-Smith G, Taaffe DR. Bone loss in Crohn’s disease: exercise as a potential countermeasure. Inflamm Bowel Dis. 2005;11:1108-1118. [PMID: 16306774 DOI: 10.1097/01.mib.0000192325.28168.08] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
118 Juillerat P, Vader J, Felley C, Pittet V, Gonvers J, Mottet C, Bemelman WA, Lémann M, Öresland T, Michetti P, Froehlich F. Appropriate maintenance treatment for Crohn's disease: Results of a multidisciplinary international expert panel — EPACT II. Journal of Crohn's and Colitis 2009;3:241-9. [DOI: 10.1016/j.crohns.2009.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
119 Erim DO, Mahendraratnam N, Okafor PN, Wheeler SB. The Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn's Disease Patients with Adalimumab Non-response in the USA. J Crohns Colitis 2015;9:669-75. [PMID: 25987351 DOI: 10.1093/ecco-jcc/jjv090] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
120 Kitiyakara T, Hayat J, Mcintyre AS. Cost-effectiveness of thiopurine methyltransferase genotype screening in IBD. Aliment Pharmacol Ther 2005;21:790-1. [DOI: 10.1111/j.1365-2036.2005.02358.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
121 Lichtenstein GR, Cuffari C, Kane SV, Hanauer S, Present DH. Maintaining remissions across the lifespan: a roundtable discussion with Crohn's disease experts. Inflamm Bowel Dis 2004;10 Suppl 2:S11-21. [PMID: 15475769 DOI: 10.1097/00054725-200407002-00003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
122 Austin GL, Herfarth HH, Sandler RS. A critical evaluation of serologic markers for inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:545-7. [PMID: 17433787 DOI: 10.1016/j.cgh.2007.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
123 Hanauer SB. Crohn's disease: step up or top down therapy. Best Practice & Research Clinical Gastroenterology 2003;17:131-7. [DOI: 10.1053/bega.2003.0361] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
124 Knigge KL. Inflammatory bowel disease. Clin Cornerstone. 2002;4:49-60. [PMID: 12739326 DOI: 10.1016/s1098-3597(02)90005-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
125 Li K, Friedman JR, Chan D, Pollack P, Yang F, Jacobstein D, Brodmerkel C, Gasink C, Feagan BG, Sandborn WJ, Rutgeerts P, De Hertogh G. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease. Gastroenterology 2019;157:1019-1031.e7. [PMID: 31279870 DOI: 10.1053/j.gastro.2019.06.037] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 8.7] [Reference Citation Analysis]
126 Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, De Vitis I, Guidi L, Gasbarrini A. Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol. 2009;104:1575-1586. [PMID: 19491875 DOI: 10.1038/ajg.2009.162] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
127 Katz JA. Management of inflammatory bowel disease in adults. J Dig Dis 2007;8:65-71. [PMID: 17532817 DOI: 10.1111/j.1443-9573.2007.00287.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
128 . Doença de Crohn intestinal: manejo. Revista da Associação Médica Brasileira 2011;57:10-3. [DOI: 10.1590/s0104-42302011000100006] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
129 Sandborn WJ. What's new: innovative concepts in inflammatory bowel disease. Colorect Dis 2006;8:3-9. [DOI: 10.1111/j.1463-1318.2006.00985.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
130 Fathi F, Majari-kasmaee L, Mani-varnosfaderani A, Kyani A, Rostami-nejad M, Sohrabzadeh K, Naderi N, Zali MR, Rezaei-tavirani M, Tafazzoli M, Arefi-oskouie A. 1 H NMR based metabolic profiling in Crohn's disease by random forest methodology: NMR-based metabonomics. Magn Reson Chem 2014;52:370-6. [DOI: 10.1002/mrc.4074] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
131 Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther. 2004;20:1337-1346. [PMID: 15606396 DOI: 10.1111/j.1365-2036.2004.02285.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 81] [Article Influence: 5.6] [Reference Citation Analysis]
132 Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-260. [PMID: 11487534 DOI: 10.1053/gast.2001.26279] [Cited by in Crossref: 798] [Cited by in F6Publishing: 690] [Article Influence: 38.0] [Reference Citation Analysis]
133 Kwapisz L, Jairath V, Khanna R, Feagan B. Pharmacokinetic drug evaluation of budesonide in the treatment of Crohn's disease. Expert Opin Drug Metab Toxicol 2017;13:793-801. [PMID: 28612627 DOI: 10.1080/17425255.2017.1340454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
134 Mahadevan U, Loftus EV, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002;97:910-914. [PMID: 12008668 DOI: 10.1111/j.1572-0241.2002.05608.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 91] [Article Influence: 4.9] [Reference Citation Analysis]
135 Schnitzler F, Fidder H, Ferrante M, Ballet V, Noman M, Van Assche G, Spitz B, Hoffman I, Van Steen K, Vermeire S. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17:1846-1854. [PMID: 21830263 DOI: 10.1002/ibd.21583] [Cited by in Crossref: 127] [Cited by in F6Publishing: 117] [Article Influence: 11.5] [Reference Citation Analysis]
136 Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther. 2002;16:1509-1517. [PMID: 12182751 DOI: 10.1046/j.1365-2036.2002.01289.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 69] [Article Influence: 4.6] [Reference Citation Analysis]
137 Moyer MS. 5-Aminosalicylate Therapy. In: Mamula P, Markowitz JE, Baldassano RN, editors. Pediatric Inflammatory Bowel Disease. Boston: Springer US; 2008. pp. 317-28. [DOI: 10.1007/978-0-387-73481-1_24] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
138 Babu D, Thapa D, Lee JS, Park S, Kim AR, Kim YH, Yang HC, Kim J. Inhibitory effects of an aqueous extract of Cornus kousa Burg. Leaves on TNF-α-induced chemokine expression and monocyte adhesion to human colonic epithelial cells. Arch Pharm Res 2009;32:91-8. [DOI: 10.1007/s12272-009-1122-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
139 Gheorghe C, Pascu O, Gheorghe L, Iacob R, Dumitru E, Tantau M, Vadan R, Goldis A, Balan G, Iacob S. Epidemiology of inflammatory bowel disease in adults who refer to gastroenterology care in Romania: a multicentre study. Eur J Gastroenterol Hepatol. 2004;16:1153-1159. [PMID: 15489575 DOI: 10.1097/00042737-200411000-00012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 2.8] [Reference Citation Analysis]
140 Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB;  American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease. Gastroenterology. 2003;125:1508-1530. [PMID: 14598268 DOI: 10.1016/j.gastro.2003.08.025] [Cited by in Crossref: 389] [Cited by in F6Publishing: 291] [Article Influence: 20.5] [Reference Citation Analysis]
141 Michetti P, Stelle M, Juillerat P, Gassull M, Heil FJ, Stange E, Mottet C, Gonvers J, Pittet V, Vader J, Froehlich F, Felley C. Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel—EPACT II. Journal of Crohn's and Colitis 2009;3:232-40. [DOI: 10.1016/j.crohns.2009.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
142 Lichtenstein GR, Hanauer SB, Kane SV, Present DH. Crohn’s Is Not a 6-Week Disease: Lifelong Management of Mild to Moderate Crohn’s Disease. Inflammatory Bowel Diseases 2004;10:S2-S10. [DOI: 10.1097/00054725-200407002-00002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
143 Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OØ, Innes A. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129:807-818. [PMID: 16143120 DOI: 10.1053/j.gastro.2005.06.064] [Cited by in Crossref: 419] [Cited by in F6Publishing: 369] [Article Influence: 24.6] [Reference Citation Analysis]
144 Rivkin A. Certolizumab pegol for the management of Crohn’s disease in adults. Clin Ther. 2009;31:1158-1176. [PMID: 19695385 DOI: 10.1016/j.clinthera.2009.06.015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
145 Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R. Extracorporeal photopheresis for the treatment of refractory Crohn’s disease: results of an open-label pilot study. Inflamm Bowel Dis. 2009;15:829-836. [PMID: 19130617 DOI: 10.1002/ibd.20833] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
146 Shao LM, Chen MY, Cai JT. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease. Aliment Pharmacol Ther. 2009;29:605-614. [PMID: 19183161 DOI: 10.1111/j.1365-2036.2009.03929.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
147 Altschuler A, Collins B, Lewis JD, Velayos F, Allison JE, Hutfless S, Liu L, Herrinton LJ. Gastroenterologists’ attitudes and self-reported practices regarding inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:992-999. [PMID: 18300277 DOI: 10.1002/ibd.20416] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
148 Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004;127:723-729. [PMID: 15362027 DOI: 10.1053/j.gastro.2004.06.002] [Cited by in Crossref: 330] [Cited by in F6Publishing: 285] [Article Influence: 18.3] [Reference Citation Analysis]
149 Musch E, Lutfi T, von Stein P, Zargari A, Admyre C, Malek M, Löfberg R, von Stein OD. Topical Treatment with the Toll-like Receptor Agonist DIMS0150 Has Potential for Lasting Relief of Symptoms in Patients with Chronic Active Ulcerative Colitis by Restoring Glucocorticoid Sensitivity: . Inflammatory Bowel Diseases 2013;19:283-92. [DOI: 10.1002/ibd.23019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
150 Cohen RD. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006;24:465-74. [DOI: 10.1111/j.1365-2036.2006.03010.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
151 Dudley-Brown S, Nag A, Cullinan C, Ayers M, Hass S, Panjabi S. Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy. Gastroenterol Nurs. 2009;32:327-339. [PMID: 19820441 DOI: 10.1097/sga.0b013e3181bb1484] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
152 Sandborn WJ, Feagan BG. Review article: mild to moderate Crohn’s disease--defining the basis for a new treatment algorithm. Aliment Pharmacol Ther. 2003;18:263-277. [PMID: 12895211 DOI: 10.1046/j.1365-2036.2003.01661.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
153 Gonvers J, Juillerat P, Mottet C, Pittet V, Felley C, Vader J, Michetti P, Froehlich F. Maintenance of Medically Induced Remission of Crohn’s Disease. Digestion 2008;76:116-29. [DOI: 10.1159/000111026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
154 Zhang S, Qing Q, Wang Q, Xu J, Zhi F, Park PW, Zhang Y, Chen Y. Syndecan-1 and Heparanase: Potential Markers for Activity Evaluation and Differential Diagnosis of Crohnʼs Disease. Inflammatory Bowel Diseases 2013;19:1025-33. [DOI: 10.1097/mib.0b013e318280298f] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
155 El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101:311-317. [PMID: 16454836 DOI: 10.1111/j.1572-0241.2006.00384.x] [Cited by in Crossref: 106] [Cited by in F6Publishing: 88] [Article Influence: 6.6] [Reference Citation Analysis]
156 Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630. [PMID: 16678077 DOI: 10.1016/j.cgh.2006.03.002] [Cited by in Crossref: 633] [Cited by in F6Publishing: 547] [Article Influence: 39.6] [Reference Citation Analysis]
157 Albuquerque ICD, Carvalho RBD, Lopes JM, Pincinato AL, Monteiro EP, Formiga GJS. Doença de Crohn: fatores de risco para recidiva no pós-operatório. Rev bras colo-proctol 2008;28:36-9. [DOI: 10.1590/s0101-98802008000100005] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
158 Massironi S, Losco A, Basilisco G. Drug side-effects in IBD. Aliment Pharmacol Ther 2002;16:1831. [PMID: 12269978 DOI: 10.1046/j.1365-2036.2002.t01-1-01329_1.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
159 Kawalec P, Moćko P, Pilc A, Radziwon-zalewska M, Malinowska-lipień I. Vedolizumab Compared with Certolizumab in the Therapy of Crohn Disease: A Systematic Review and Indirect Comparison. Pharmacotherapy 2016;36:861-9. [DOI: 10.1002/phar.1784] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]